Loading…
Underlying
Underlying Price
$8.33
Type
Put
Strike
7.5
Expiration
Oct 30, 2026
DTE
10d
Moneyness
OTM
Intrinsic
$0.00
IBRX 7.5 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.05 | +25.00% | 8 | 239 |
| Oct 30, 2026 | 10d | $0.12 | -40.00% | 1 | 62 |
| Nov 6, 2026 | 17d | $0.32 | -20.00% | 10 | 22 |
| Nov 13, 2026 | 24d | $0.28 | -6.67% | 10 | 7 |
| Nov 27, 2026 | 38d | $0.43 | +0.00% | 2 | 25 |
| Jan 15, 2027 | 87d | $0.90 | +20.00% | 121 | 22,728 |
| Jan 21, 2028 | 458d | $1.95 | -9.30% | 125 | 9,702 |
IBRX Nearby Strikes · Oct 30, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 4.5 P | — | — | 0 | 0 | OTM |
| 5 P | — | — | 0 | 0 | OTM |
| 5.5 P | — | — | 0 | 0 | OTM |
| 6 P | $0.05 | +0.00% | 10 | 21 | OTM |
| 6.5 P | $0.05 | -85.71% | 5 | 18 | OTM |
| 7 P | $0.05 | -50.00% | 1 | 78 | OTM |
| 7.5 P | $0.12 | -40.00% | 1 | 62 | OTM |
| 8 P | $0.25 | +92.31% | 2 | 150 | OTM |
| 8.5 P | $0.35 | +75.00% | 33 | 1,052 | ITM |
| 9 P | $0.50 | +72.41% | 53 | 599 | ITM |
| 9.5 P | $0.75 | +50.00% | 39 | 300 | ITM |
| 10 P | $1.15 | +76.92% | 2 | 259 | ITM |
| 10.5 P | $1.32 | +7.32% | 1 | 54 | ITM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.